What Allurion Technologies does

Allurion Technologies, Inc. is a publicly traded medical device and digital health company (NYSE: ALUR) that developed the Allurion Program, a full-stack weight-loss platform built around the Allurion Smart Capsule — an FDA-approved swallowable intragastric balloon placed during a 15-minute outpatient visit without surgery, endoscopy, or anesthesia. The balloon is enclosed in a vegetarian, non-animal-derived, degradable capsule, filled with 550ml of liquid once in the stomach, and remains in place for approximately 16 weeks before automatically emptying via a patented Release Valve and being naturally excreted. The platform integrates the balloon with the Allurion Connected Scale (Bluetooth-enabled body composition tracking), the Allurion App, the Allurion Virtual Care Suite (telehealth and care team dashboard), the Allurion Behavior Change Program, and Coach Iris, an LLM-powered AI health coach. The company holds 50+ patents and has published 30+ peer-reviewed studies supporting clinical claims of 14% total body weight loss after one cycle and 2.2x more weight loss than diet alone.

Allurion generates revenue primarily through B2B sales of the Smart Capsule medical device to a global network of certified partner clinics, with additional revenue from combination therapy programs pairing the balloon with discounted tirzepatide (Mounjaro) in select markets such as Argentina. Pricing is set by partner clinics rather than disclosed publicly, and the company is exploring self-insured employer partnerships to expand U.S. patient access. The company has treated over 200,000 patients across 78 countries internationally, received FDA PMA approval in February 2026, and began U.S. commercial launch in April 2026 with first shipments and patient treatments. Headquartered in Natick, Massachusetts with manufacturing at the same location and a European regional office in Paris, Allurion also distributes via regional partners including ProSurg Medical in Brazil and Bionut/Farmastar in Argentina.

The business model carries significant execution and financial complexity: 2024 revenue was approximately $32 million but Q3 2025 revenue declined ~50% year-over-year, the company carried $83 million in debt (eliminated via Series B Convertible Preferred Stock in November 2025) and $37 million in negative LTM free cash flow, and the share price fell to a market capitalization of approximately $14.37 million, triggering NYSE delisting proceedings in March 2026 with a 1-for-15 reverse stock split announced for June 2026. The company faces a pending patent infringement lawsuit from Medtimo in U.S. District Court while simultaneously executing its first U.S. commercial launch — making it a turnaround-stage public equity story rather than a steady-state business.

Name

Allurion Technologies

Legal name

Allurion Technologies, Inc.

Website

https://allurion.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

Allurion Technologies is a publicly traded medical device company (NYSE: ALUR) that markets the FDA-approved Allurion Smart Capsule, a swallowable gastric balloon placed without surgery or endoscopy, combined with a digital health platform for adults with obesity (BMI 30-40). It has treated over 200,000 patients across 78 countries and launched commercially in the U.S. in April 2026.

Ownership category

akta.pro rank

Product category

Bariatric Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Wearable Injectors & On-Body Delivery Systems (HLAHAIAE)

Keywords

• Gastric balloon systems
• Weight loss devices
• Obesity treatment solutions
• Intragastric balloon therapy
• Digital health coaching

Headquarters

HQ city

Wellesley

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations, Infrastructure

Revenue model

1. Medical Device Sales (Smart Capsule): Revenue generated from the sale of the Allurion Gastric Balloon System through certified partner clinics. The balloon is a medical device that remains in the stomach for approximately 4 months before passing naturally. Treatment involves a single device per cycle.
2. Combination Therapy Programs: Partnership with Bionut and Farmastar to offer discounted tirzepatide (Mounjaro) alongside the Allurion Smart Capsule as part of a comprehensive weight loss therapy program.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Allurion Technologies develops and manufactures the Allurion Gastric Balloon System, marketed as the Allurion Program — a swallowable, procedureless intragastric balloon for weight loss in adults with obesity. The company pairs the physical Smart Capsule with a connected digital health ecosystem (Allurion App, Virtual Care Suite, Connected Scale, Health Tracker, and Coach Iris AI) to support patients and clinicians across a roughly 4-month program.

Product overview

Allurion Technologies offers the Allurion Program, a full-stack weight-loss platform centered on the FDA-approved Allurion Smart Capsule — a swallowable intragastric balloon placed during a 15-minute office visit without surgery, endoscopy, or anesthesia. The platform integrates the balloon with expert nutrition coaching, behavioral support, and a digital ecosystem comprising the Allurion Connected Scale, Allurion App, Virtual Care Suite, and Coach Iris AI health coach. Healthcare providers access the platform through the Allurion Partner Program with training resources from the 4C Hub & 4C Learning Lab. The company has also launched a combination therapy initiative pairing the balloon with discounted tirzepatide (Mounjaro).

Differentiator

Problem solved

Functional benefit

Brands

• Allurion Program: Full-stack weight-loss platform combining the Allurion Balloon with medical care, behavioral support, and digital tools
• Allurion Smart Capsule
• Allurion Virtual Care Suite
• Coach Iris
• Elipse Program
• Elipse Balloon

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Bionut and FarmastarcoreChannel Partner/ Reseller/ Distributor · 3 February 2026Partnership with Bionut and Farmastar in Argentina to offer discounted Mounjaro (tirzepatide) for use with the Allurion Smart Capsule as part of a weight loss therapy. The collaboration aims to improve outcomes for obesity treatment by combining low doses of Mounjaro with the capsule, with plans to expand similar initiatives to other regions.
• ProSurg MedicalcoreChannel Partner/ Reseller/ Distributor · 18 November 2025Strategic distribution partnership with ProSurg Medical in Brazil to advance metabolically healthy weight loss. The partnership leverages ProSurg's extensive experience and healthcare network in Brazil to expand access to Allurion's obesity care products and programs.
• MedtimominorOthers · 9 October 2025Medtimo filed a patent infringement lawsuit in U.S. District Court against Allurion Technologies, accusing it of infringing three patents related to gastric balloon system technology. This is an adversarial legal relationship, not a partnership.

Scale indicators9 records

Recent moves7 records

Expansion highlights8 records

Broad incumbents

• Medtronic: Medtronic is a broad incumbent medical device leader with an existing bariatric and metabolic portfolio. Its former CEO Omar Ishrak sits on Allurion's board, underscoring the strategic relevance of Allurion's platform to established medtech.
• Eli Lilly: Eli Lilly markets Mounjaro and Zepbound (tirzepatide), the leading GLP-1 obesity drugs. Allurion's combination therapy partnership with tirzepatide in Argentina positions it as both a potential complement and a substitute to Lilly's pharmaceutical franchise.
• Boston Scientific: Boston Scientific acquired Apollo Endosurgery and now owns the Orbera intragastric balloon, making it both an investor/owner of Allurion's most direct competitor and a broad medtech incumbent with overlapping bariatric and endoscopic franchises.
• Novo Nordisk: Novo Nordisk markets Wegovy and Ozempic (semaglutide), defining the GLP-1 standard of care for obesity and shaping the competitive context in which Allurion's non-pharmacologic balloon alternative must compete.

Direct peers

• Spatz Medical: Spatz Medical makes the Spatz3 adjustable gastric balloon, a direct competitor in the intragastric balloon category. Both companies target the same bariatric patient population with non-surgical, endoscopic or procedureless balloon placement approaches.
• Obalon Therapeutics: Obalon developed a swallowable gas-filled gastric balloon and was a direct U.S. competitor in the procedureless balloon category. Allurion's FDA approval positions it to capture share that Obalon struggled to convert commercially.
• ReShape Lifesciences: ReShape Lifesciences markets the LAP-BAND adjustable gastric banding system and previously offered the ReShape intragastric balloon. It competes with Allurion in the non-surgical/endoluminal obesity device space.
• Apollo Endosurgery (Orbera): Apollo Endosurgery made the Orbera intragastric balloon system, the most direct competitor to Allurion's Smart Capsule. Acquired by Boston Scientific in 2023, Apollo/Orbera competed head-to-head in the swallowable and endoscopic gastric balloon space and shaped the clinical evidence base Allurion now leverages.

Emerging players

• USGI Medical: USGI Medical develops endoscopic incisionless bariatric devices such as the g-Cath EZ Suture Anchor Delivery System. It competes in the same endoluminal obesity therapy space as Allurion with overlapping physician customer targets.
• Endo Tools Therapeutics: Endo Tools Therapeutics is an emerging player in endoscopic bariatric and metabolic therapies. It targets the same minimally-invasive obesity treatment category as Allurion but with a different delivery modality, representing a future potential competitor or partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/alluriontech
• YouTubeyoutube.com/c/AllurionTechnologies
• Facebookfacebook.com/258935737519339
• LinkedInlinkedin.com/company/allurion-technologies
• Instagraminstagram.com/allurionballoonofficial

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds16 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allurion Technologies